FREE 2-DAY SHIPPING ON ORDERS $200+

Blog

Mazdutide vs Retatrutide: Dual Agonist vs Triple Agonist Trial Results

Two matching fume hoods side by side along one wall of a bright, empty pharmacology lab, sashes lowered to the same height, with daylight from tall windows across a pale floor

Mazdutide and retatrutide were both designed in Eli Lilly’s labs, both go in once a week, and both lean on glucagon, the hormone that speeds up how much energy the body spends and clears fat from the liver. Mazdutide pairs glucagon with GLP-1. Retatrutide adds a third signal, GIP, the one tirzepatide is built on.

From there the two went separate ways. Lilly licensed mazdutide to Innovent Biologics for China, where it has been approved for weight management since June 2025, and its longest published trial reached 16.65% over 60 weeks. Retatrutide stayed with Lilly and took 28.3% off at 80 weeks. The two have never shared a trial, so every number below comes from separate studies, and each one reads best next to who was in it.

Simms Research stocks one of the pair. Retatrutide (GLP-3) is sold in four vial sizes with its current certificate of analysis posted; mazdutide isn’t carried.

Mazdutide vs retatrutide: the key differences

Two receptors against three, an approved medicine in one country against a drug still awaiting its first filing, and a lead for retatrutide on every weight result published so far.

PointMazdutideRetatrutide
Receptors it acts onTwo: GLP-1 and glucagonThree: GIP, GLP-1 and glucagon
Code namesLY3305677 at Lilly, IBI362 at InnoventLY3437943
Who runs the trialsInnovent in China, Lilly in the USLilly, worldwide
Top dose in the obesity trials16mg12mg
About a year, no diabetes14.01% at 48 weeks on 6mg24.2% at 48 weeks on 12mg
Longest trial16.65% at 60 weeks on 9mg28.3% at 80 weeks on 12mg
Against semaglutide, type 2 diabetes10.29% against 6.0% at 32 weeks20.9% against 9.4% at 80 weeks
ApprovedChina only: weight (June 2025), type 2 diabetes (September 2025)Not yet; Lilly to submit it in the US early in 2027
Furthest US trialPhase 2Phase 3
Stocked by Simms ResearchNoRetatrutide (GLP-3), 10mg to 60mg, $84 to $259
Automated peptide synthesizer on a white bench with a row of clear reagent bottles and thin tubing feeding a small glass reaction vessel in side daylight

How mazdutide and retatrutide work

Both turn hunger down through the GLP-1 receptor and raise the body’s energy use through the glucagon receptor. Retatrutide adds a third target, the GIP receptor.

What is mazdutide?

A weekly peptide that switches on the GLP-1 and glucagon receptors together, the same pair a gut hormone called oxyntomodulin reaches after a meal. Lilly designed it under the code LY3305677 and handed the China rights to Innovent, which develops it there as IBI362.

Innovent ran the large trials: two Phase 3 studies for weight (GLORY-1 and GLORY-2) and three for type 2 diabetes (DREAMS-1, -2 and -3), all in Chinese adults. Lilly kept the rest of the world and has tested it in the US at higher doses than China uses, up to 16mg, in a 179-person Phase 2 published in August 2026.

What is retatrutide?

A weekly peptide built on a GIP backbone, coded LY3437943, which Lilly designed and develops worldwide. It acts on the glucagon and GLP-1 receptors about equally and on GIP more strongly. In mice, GIP and GLP-1 cut food intake while glucagon raised the energy burned (Coskun, Cell Metabolism, 2022).

Neither is a trimmed-down copy of the other. What Is GLP-3 (Retatrutide)? explains how retatrutide came to be sold as GLP-3 by research suppliers.

The GIP question: what the third receptor adds

Appetite from GLP-1, a higher burn from glucagon, and in retatrutide an extra push from GIP.

Both drugs share two jobs. GLP-1 delays stomach emptying and turns hunger down, the engine behind semaglutide. Glucagon lifts energy spending and pulls fat out of the liver, a job neither semaglutide nor tirzepatide does.

GIP is the difference. It is the hormone tirzepatide pairs with GLP-1, and that pairing beat semaglutide in their 72-week head-to-head, 20.2% against 13.7% (Aronne, New England Journal of Medicine, 2025). Retatrutide stacks GIP on top of mazdutide’s pair, which is the whole of the dual-versus-triple question.

GIP also boosts insulin release after meals and acts on fat tissue directly. In animal studies it blunted the nausea and vomiting that GLP-1 drugs cause (Borner, Diabetes, 2021).

Liver fat: the glucagon effect both share

On MRI scans, both drugs cut liver fat by roughly three-quarters at their higher doses. Glucagon acts on the liver directly, telling it to burn the fat it has stored and make less of it.

Retatrutide’s figures come from a 98-person Phase 2 group with fatty liver disease. At 24 weeks, liver fat fell 81.4% on 8mg and 82.4% on 12mg, against a 0.3% rise on placebo, and 86% of the 12mg group were back under 5%, the normal range (Sanyal, Nature Medicine, 2024).

Mazdutide’s come from GLORY-2. Among adults without diabetes who started with at least 10% liver fat, 9mg cut it by 71.9% by week 60 (Innovent, November 2025).

Neither has finished a trial on liver inflammation and scarring, the harder target. Innovent’s 60-week trial in MASH, the inflamed form of fatty liver disease, finished its main phase in September 2026, and Lilly is testing retatrutide in a Phase 3 liver study set to run to 2030.

Mazdutide vs retatrutide trial results

Mazdutide trial results

14% at 48 weeks on 6mg and 16.65% at 60 weeks on 9mg in China, and 18.1% at 32 weeks on 16mg in the US, with placebo groups near zero. GLORY-1 enrolled 610 Chinese adults with overweight or obesity, GLORY-2 461 with a BMI of 30 or more, and the US Phase 2 trial 179 adults without diabetes.

In type 2 diabetes, the three DREAMS trials ran 24 to 32 weeks. On 6mg, mazdutide took off 7.81% against 1.26% on placebo in DREAMS-1, 5.76 points more than dulaglutide 1.5mg in DREAMS-2, and 10.29% against 6.0% on semaglutide 1mg in DREAMS-3.

GLORY-1 is the trial behind the China approval: on 4mg and 6mg, 35.7% and 49.5% of people lost 15% or more of their starting weight by week 48, against 2.0% on placebo (Ji, New England Journal of Medicine, 2025). GLORY-2 took heavier adults to 9mg for 60 weeks; the journal paper puts the loss at 16.65% against 1.50% (Gao, JAMA, 2026); Innovent’s own count came to 18.55%, and 20.1% for those without diabetes.

The US trial is the one to hold against retatrutide, because its entry rules match retatrutide’s Phase 2: BMI 30 and up, or 27 with a weight-related condition, and no diabetes. At week 32, 10mg had taken off 15.6% and 16mg 18.1%, and both kept going to week 48 (Hsia, Lancet Diabetes and Endocrinology, 2026).

Retatrutide trial results

24.2% at 48 weeks in Phase 2, then 28.7% at 68 weeks and 28.3% at 80 weeks in Phase 3, with placebo groups near 2%. In the 338-person Phase 2 trial, 83% of the 12mg group had lost 15% or more by week 48 (Jastreboff, New England Journal of Medicine, 2023).

TRIUMPH-1 followed with 2,339 adults over 80 weeks: 19.0% on 4mg, 25.9% on 9mg and 28.3% on 12mg, against 2.2% on placebo. TRIUMPH-4, in obesity with knee arthritis, reported 28.7% at 68 weeks in December 2025. In type 2 diabetes, TRANSCEND-T2D-2 gave 1,298 adults retatrutide or semaglutide 2mg for 80 weeks, and 12mg took off 20.9% against 9.4%.

Mazdutide vs retatrutide side by side

Retatrutide leads at every point where the trials line up, and the gap grows the longer they run. In US adults under the same entry rules, mazdutide 16mg reached 18.1% at 32 weeks; retatrutide 12mg reached 17.5% at 24 weeks and 24.2% at 48. The longest trials stand at 16.65% after 60 weeks on mazdutide 9mg against 28.3% after 80 weeks on retatrutide 12mg.

Counting matters too. Lilly’s headline TRIUMPH figures cover people while they stayed on the drug, while GLORY-1 counts everyone randomized. Counted GLORY-1’s way, TRIUMPH-1’s top dose comes to 25.0% against 3.9% on placebo (Jastreboff, New England Journal of Medicine, 2026), still well clear.

Semaglutide is the nearest thing to a shared ruler: mazdutide 6mg finished about four points ahead of semaglutide 1mg over 32 weeks, and retatrutide 12mg more than doubled semaglutide 2mg over 80. How Long Does Retatrutide Take to Work? follows retatrutide’s result checkpoint by checkpoint.

Population differences: Chinese vs Western trial data

Mazdutide’s Phase 3 numbers come from Chinese adults and retatrutide’s mostly from Western ones, so the two groups differed before either drug was given.

GLORY-1 used China’s own cut-offs, a BMI of 28 and up, or 24 with a weight-related condition, and its 610 adults started at 87.2kg (192 lb) and a BMI of 31.1. GLORY-2’s 461 adults started at 94.0kg (207 lb), a BMI of 34.3 and an average age of 34. Retatrutide’s trials used the Western cut-offs of 30, or 27 with a condition, and their participants started roughly 30 to 55 lb heavier.

Asian adults run into type 2 diabetes and heart disease at lower BMIs than European adults, which is why lower cut-offs apply to them (WHO Expert Consultation, Lancet, 2004). A percentage from China starts from a lighter body and doesn’t line up one to one with a TRIUMPH figure.

Time is the other gap: mazdutide’s longest trial stopped at 60 weeks and retatrutide’s ran to 80.

Stainless conveyor in a bright cleanroom carrying rows of small empty clear glass vials behind clear guards

Is mazdutide better than retatrutide?

For weight loss, no. Retatrutide comes out ahead at every point the separate trials allow, and by the widest margin over the longest stretch: 28.3% at 80 weeks against mazdutide’s 16.65% at 60.

Mazdutide’s strengths are real. It is a working medicine in China with five Phase 3 trials behind it, its 4mg and 6mg doses were about as easy to stay on as placebo, and its 16mg dose in the US reached 18.1% by week 32, close to retatrutide’s 17.5% at week 24. Retatrutide answers with the size of the result and the depth behind it: Phase 3 trials in thousands of people across obesity, diabetes, knee arthritis and heart disease, all pointing the same way.

When to choose retatrutide

For the largest weight loss and liver-fat cut on record, and for work on all three receptors at once. Its results also reach past weight: in TRIUMPH-1, 12mg cut sleep apnea events by 31.7 an hour against 9.9 on placebo and eased knee arthritis pain (Jastreboff, New England Journal of Medicine, 2026).

When to choose mazdutide

For a protocol that needs GLP-1 and glucagon without GIP. Run next to retatrutide, it measures what GIP contributes. It is also the one to read for East Asian adults, in whom all of its Phase 3 trials were run.

Mazdutide vs retatrutide side effects

The same stomach effects on both, mostly mild to moderate. Mazdutide’s top dose in China brought more vomiting; retatrutide’s brought more people stopping.

Side effectMazdutide 9mg, 60 weeksPlaceboRetatrutide 12mg, 80 weeksPlacebo
Nausea46.9%3.2%42.4%14.8%
Vomiting53.1%1.3%25.3%4.8%
Diarrhea39.4%6.5%32.0%13.5%
Stopped over side effects2.9%0%11.3%4.9%

The mazdutide column comes from GLORY-2 (Gao, JAMA, 2026) and the retatrutide column from TRIUMPH-1, reported by Lilly in May 2026. GLORY-2’s placebo group logged far less nausea than TRIUMPH-1’s, so the gap to placebo says more than the raw rate.

Lower doses change the picture. On mazdutide 4mg and 6mg, 1.5% and 0.5% stopped over side effects across 48 weeks, against 1.0% on placebo, and on retatrutide 4mg the figure was 4.1%. At the other end, mazdutide 16mg in the US lost 20% of its group. Retatrutide also brings dysesthesia, pins-and-needles or extra-sensitive skin, reported by between 5.1% and 12.5% of people against 0.9% on placebo, mostly mild and often gone while the drug continued.

Glucagon on its own raises blood sugar, yet both drugs lowered it in their diabetes trials. Retatrutide also raised heart rate with dose, peaking at 24 weeks and easing after (Jastreboff, New England Journal of Medicine, 2023).

Mazdutide and retatrutide dosing and reconstitution

Both are given once a week under the skin, starting low and stepping up every four weeks. Retatrutide’s Phase 3 trials started everyone at 2mg and moved through 4, 6 and 9mg to a target of 4, 9 or 12mg; the retatrutide dosage chart sets out every step. Mazdutide’s trials climbed the same way, for example 3, 6 and then 9mg at four-week steps (Ji, eClinicalMedicine, 2022), and Lilly’s US trial went on to 10 and 16mg.

Research retatrutide comes as a powder that is mixed with bacteriostatic water. A 10mg vial with 1mL of water reads 10 units per mg on an insulin syringe, so the 2mg start is 20 units. How to Reconstitute Retatrutide covers every vial size, and Simms Research sells Research Water at $20 for 10mL. Mixed vials keep in the fridge at 2 to 8°C.

For research now, Simms Research carries Retatrutide (GLP-3) in four sizes, from $84 for 10mg to $259 for 60mg, which takes the cost per mg from $8.40 down to $4.32. Its current report, dated July 16, 2026, drew on three vials sold as 10mg and measured 10.68mg at 99.611% purity, with identity confirmed by LC-MS, the test that reads a peptide’s mass. Retatrutide’s is 4,731 g/mol; mazdutide’s is about 4,476.

Endotoxin, heavy metal and microbial results are listed on the retatrutide lab results page, and the retatrutide calculator converts a weekly amount to units on the syringe for each vial.

Can you take mazdutide and retatrutide together?

No study has combined them, and they would double up, since both act on the GLP-1 and glucagon receptors. Lilly’s combination work goes another way, adding the amylin drug eloralintide to tirzepatide, covered in Eloralintide vs Retatrutide: New Trial Results and Key Differences.

Mazdutide vs retatrutide vs tirzepatide

Tirzepatide drops glucagon, mazdutide drops GIP, and retatrutide keeps all three.

Tirzepatide, sold as Zepbound and Mounjaro, is GIP plus GLP-1 and the only one of the three approved in the US. Its 15mg top dose took off 20.9% at 72 weeks against 3.1% on placebo (Jastreboff, New England Journal of Medicine, 2022), above mazdutide’s results in China and below retatrutide’s 28.3% at 80 weeks.

The trial that comes closest to pricing glucagon’s share is TRIUMPH-5, retatrutide against tirzepatide in about 800 adults with obesity over 80 weeks. Its main phase is set to finish in November 2026; until it reports, the retatrutide vs tirzepatide comparison sets their separate results dose by dose. Simms Research’s tirzepatide is Tirzepatide (GLP-2), $65 to $186 across four vial sizes.

Tall white NMR magnet standing in a bright, empty room beside a low bench with a small rack of thin glass sample tubes and tall windows

Is mazdutide FDA approved?

No. Mazdutide is approved only in China, and Lilly’s US trials have reached Phase 2.

China approved it for long-term weight management on June 27, 2025, on the strength of GLORY-1, and for blood-sugar control in type 2 diabetes in September 2025. Innovent filed the 9mg dose there in late 2025.

In the US, Lilly’s registered mazdutide studies stop at Phase 2: the obesity trial published in August 2026, a trial in alcohol use disorder finished in March 2026 and a weight study still recruiting. An FDA filing needs Phase 3 results first. Lilly’s quarterly update of October 29, 2026 listed milestones for retatrutide and eloralintide and none for mazdutide.

Is mazdutide available in the USA?

Not as a prescription. Retatrutide is the nearer of the two, with Lilly expecting to submit it to the FDA early in 2027; When Will Retatrutide Be FDA Approved? has the review timeline.

Frequently asked questions

Is mazdutide the same as retatrutide?

No. They are different peptides with different formulas, C207H317N45O65 for mazdutide and C221H342N46O68 for retatrutide, and mazdutide leaves out the GIP receptor.

Is mazdutide the same as survodutide?

No. Survodutide is also a GLP-1 and glucagon dual agonist, but it comes from Boehringer Ingelheim and Zealand Pharma; mazdutide is Lilly’s design.

Does Simms Research sell mazdutide?

No. In this family it stocks Tirzepatide (GLP-2) and Retatrutide (GLP-3).

Is Simms Research legit?

Simms Research is a US supplier that has every batch tested by an independent ISO-certified lab before sale and posts the reports in its lab results library. Orders before 5 PM Eastern ship the same day, and its Free Delivery Guarantee replaces or refunds a parcel lost, stolen after its delivery scan or damaged. Support answers by email and phone on weekdays.

Is there a coupon code on this page?

None, and no affiliate links. Simms Research takes 5% off three or more vials and 10% off six or more, and Simms Rewards points on every order turn into free products.

Keep exploring

Verify the underlying batch data

Compare published methods and results, then open the source certificate for the batch you are evaluating.

Browse lab results